Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARVN vs MRVI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARVN Captures Overall Composite Edge (52.9 HOLD vs 49.0 HOLD), While MRVI Leads 4–2 on Growth & Valuation Pillars

ARVN Overall Winner 6-Pillar Tally: ARVN 2 – 4 MRVI Matrix Metrics: ARVN 7 – 3 MRVI

As of Nov 16, 2026, Arvinas, Inc (ARVN) captures the overall head-to-head institutional edge over Maravai LifeSciences Holdings, Inc. (MRVI) on higher Unified Composite conviction (52.9/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while MRVI wins 4–2 across the 6-pillar growth and valuation breakdown. ARVN trades at $6.74 (17.9x Forward P/E, -10.1% operating margin) versus MRVI at $7.45 (N/M Forward P/E, -24.2% operating margin).

  • Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. MRVI 49.0/100 HOLD) and 1.40β · 66% Vol risk profile, whereas MRVI leads top-line expansion (+10.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile MRVI trades in a Neutral technical trend (BREAKOUT options phase, RSI 49.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARVN vs MRVI
ARVN NASDAQ Head-to-Head Winner
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57
MRVI NASDAQ
Maravai LifeSciences Holdings, Inc. Class A Common Stock
Pharmaceutical Preparations
$7.45
-1.19% 1D
Market Cap $2.0B
TTM Revenue $213M
Forward P/E N/M
Beta / 30D Vol 1.61β · 83% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 37.0 Fund 48.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $7.64 · SMA50: $7.40

6-Pillar Scorecard Institutional Category Breakdown (ARVN 2 – 4 MRVI)

Columns: Metric · ARVN · MRVI
1. Valuation Multiples ARVN
Forward P/E 17.9x N/M
Trailing P/E 17.9x N/M
PEG Ratio N/M N/M
EV / Revenue 1.3x 9.9x
2. Growth & Scale MRVI
Revenue Growth (YoY) -98.8% +10.1%
Earnings Growth (YoY) +0.0% -32.7%
TTM Revenue (USD) $275M $213M
Market Cap $449.9M $2.0B
3. Profitability & Quality ARVN
Gross Margin 96.7% 39.9%
Operating Margin -10.1% -24.2%
Net Profit Margin -3.5% -30.8%
Return on Equity (ROE) -1.8% -29.8%
4. Balance Sheet & Cash Flow MRVI
Cash Generation (TTM) -$160M -$13M
Cash Flow Margin -58.0% -5.9%
Net Cash / Leverage $81M Net Cash $103M Net Debt (0.90x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRVI
Options Structure Phase BREAKDOWN BREAKOUT
Current IV / %ile 108.7% (25th %ile) 111.8% (17th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.01x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat MRVI
OpEx & R&D Intensity N/A 64.1% of Rev ($137M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARVN (7) vs MRVI (3)
Institutional Metric ARVN MRVI Criterion Row Edge
Market Capitalization
Scale
$449.9M $2.0B Larger Scale MRVI
Trailing P/E Ratio
Valuation
17.9x N/M Lower Multiple ARVN
Forward P/E Ratio
Valuation
17.9x N/M Lower Multiple ARVN
Revenue Growth (YoY)
Growth
-98.8% +10.1% Higher Growth MRVI
Operating Margin (TTM)
Profitability
-10.1% -24.2% Higher Margin ARVN
Net Profit Margin
Profitability
-3.5% -30.8% Higher Margin ARVN
Return on Equity (ROE)
Capital Efficiency
-1.8% -29.8% Higher ROE ARVN
52-Week Range Position
Momentum
5% ($6–$15) 70% ($3–$9) Stronger Trend MRVI
Beta / 30D Volatility
Risk Regime
1.40β · 66% Vol 1.61β · 83% Vol Lower Realized Risk ARVN
Unified Institutional Score
Composite Signal
52.9 / 100 (HOLD) 49.0 / 100 (HOLD) Higher Composite ARVN
Trailing 12M Revenue (USD)
Operating Scale
$275M $213M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
96.7% 39.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.3x EV/Rev N/M PEG · 9.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$160M ($81M Net Cash) -$13M ($103M Net Debt (0.90x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRVI +13.02 pp
ARVN: -3.3% · MRVI: +9.72%
3M Horizon MRVI +57.0 pp
ARVN: -27.21% · MRVI: +29.79%
6M Horizon MRVI +105.83 pp
ARVN: -23.23% · MRVI: +82.6%
1Y Horizon MRVI +162.63 pp
ARVN: -33.4% · MRVI: +129.23%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ARVN Revenue MRVI Revenue ARVN Op. Margin MRVI Op. Margin Margin Leader
FY2018 $10M N/A -306.3% N/A ARVN
FY2019 $20M $140M -281.4% 16.8% MRVI
FY2020 $20M $280M -554.1% 42.2% MRVI
FY2021 $50M $800M -403.4% 69.4% MRVI
FY2022 $130M $880M -200.3% 65.0% MRVI
FY2023 $80M $290M -511.5% -11.0% MRVI
FY2024 $260M $260M -95.0% -90.9% MRVI
FY2025 $260M $190M -45.1% -115.9% ARVN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRVI BREAKOUT
98d in phase · OBV DISTRIBUTION
Current IV 111.8%
IV Percentile 17th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MRVI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MRVI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.0B market capitalization and -24.2% operating margin.
OpEx & R&D Reinvestment 64.1% of Rev ($137M)
90D Engineering Disclosures 0 Published

Investor FAQ ARVN vs MRVI Key Questions & Quantitative Answers

As of Nov 16, 2026, Arvinas, Inc (ARVN) captures the overall head-to-head institutional edge over Maravai LifeSciences Holdings, Inc. (MRVI) on higher Unified Composite conviction (52.9/100 HOLD vs. 49.0/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while MRVI wins 4–2 across the 6-pillar growth and valuation breakdown. ARVN trades at $6.74 (17.9x Forward P/E, -10.1% operating margin) versus MRVI at $7.45 (N/M Forward P/E, -24.2% operating margin). Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. MRVI 49.0/100 HOLD) and 1.40β · 66% Vol risk profile, whereas MRVI leads top-line expansion (+10.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile MRVI trades in a Neutral technical trend (BREAKOUT options phase, RSI 49.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRVI leads the Growth & Scale pillar: ARVN posts -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin), compared with MRVI at +10.1% YoY revenue growth and -32.7% YoY earnings growth on $213M TTM revenue (39.9% gross margin, -24.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARVN cumulative revenue shifted +2500.0% while MRVI shifted +35.7%. In operating R&D and SG&A reinvestment, ARVN deploys N/A (0 90-day corporate R&D disclosures) versus 64.1% of Rev ($137M) (0 disclosures) for MRVI.

ARVN screens cheaper on headline valuation multiples. ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin), whereas MRVI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.9x EV/Revenue (-5.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARVN (-1.8% ROE) versus MRVI (-29.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk). By comparison, MRVI carries 111.8% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.61β · 83% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.